• home
  • about us
    • the advantage
    • key facts
    • where we are
    • where we invest
    • management team
    • funds
  • portfolio
    • companies
    • CEOs
  • news
  • investments
    • focus
      • prevention & nutraceuticals
      • medical foods OTC, Rx
      • enabling technologies
      • brands & channels
      • diagnostics
    • criteria
    • process
  • your business
  • careers
  • contact us
    • the bahamas
    • united kingdom
    • switzerland
    • new zealand

portfolio

ImmunoBiology

ImmBio is a vaccine company developing the next generation of vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe. 

Sino-UK companies announce TB vaccine partnership deal
2011-10-17
  • ImmunoBiology Ltd, is pleased to announce the signing of an initial cooperation agreement with LIBP, a subsidiary company under Sinopharm's biological products division - CNBG (China National Biotech Group).

Read the full article...

University of Nottingham and ImmunoBiology Ltd (“ImmBio”) initiate Clostridium difficile Vaccine Programme,
2010-08-10
  • ImmunoBiology ("ImmBio") is developing a novel approach to vaccines using Heat shock protein Complexes. A prophylactic vaccine could be used in various situations, such as ahead of hospitalisation, for those facing long term care and for groups most threatened by infection, such as chemotherapy patients.   

Read the full article...

Graham Clarke, ImmunoBiology:
 "Investment capital is of course central to create a valuable business but to be successful you need more than just funds from your investors."
www.immbio.com
www.immbio.com
Back to portfolio ...
Jay Garnett, Steaz
Jay Garnett, Steaz:
"Inventages has provided 'smart' capital to Steaz." More...
Terms Print Top
© 2012 Inventages